skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Recombinant Vaccinia Viral Vector RO5217790 (Code C88326)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Recombinant Vaccinia Viral Vector RO5217790

Definition: A vaccine consisting of recombinant modified vaccinia Ankara (MVA) viral vector encoding mutated forms of the genes for the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) type 16 and the human cytokine interleukin-2 (hIL2), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, recombinant vaccinia viral vector RO5217790 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing HPV E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 have been implicated in the tumorigenesis of cervical carcinoma.

Display Name: Recombinant Vaccinia Viral Vector RO5217790

Label: Recombinant Vaccinia Viral Vector RO5217790

NCI Thesaurus Code: C88326 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL413588  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Recombinant Vaccinia Viral Vector RO5217790

External Source Codes: 
PDQ Closed Trial Search ID 661166
PDQ Open Trial Search ID 661166 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C88326
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom